&lt;p&gt;LncRNA LEF1-AS1 Promotes Ovarian Cancer Development Through Interacting with miR-1285-3p&lt;/p&gt;

Zhang, Yanan; Ruan, Fang

doi:10.2147/cmar.s227652

Cited by 20 publications

(17 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the function of miR-1285-3p in OS remains uncertain. Previous studies have demonstrated that miR-1285-3p participates in the tumorigenesis of pancreatic cancer [ 31 ] and ovarian cancer [ 32 ]. The results of the present study indicated that miR-1285-3p was significantly decreased in OS cells.…”

Section: Discussionmentioning

confidence: 99%

LncRNA SNHG16 contributes to osteosarcoma progression by acting as a ceRNA of miR-1285-3p

et al. 2021

View full text Add to dashboard Cite

Background The long non-coding (lnc) RNA activated by small nucleolar RNA host gene 16 (SNHG16), which has been reported to play a vital role in a number of different types of cancer, is a novel lncRNA. However, following an osteosarcoma (OS) study, the expression pattern, biological roles, clinical values and potential molecular mechanism of SNHG16 remain unclear. In the current study, we aimed to examine its expression and possible function in osteosarcoma (OS). Method Cell proliferation was measured by colony formation assay and Cell Counting Kit-8 (CCK-8) in vitro, and xenograft transplantation assay in vivo. Meanwhile, we used transwell chambers to test cell migration and invasion was evaluated. Cell cycle and apoptosis was evaluated by flow cytometry assay. Immunoblotting and qPCR analysis was carried out to detect protein and gene expression, respectively. Luciferase reporter assay was used to predict the potential downstream genes. Results The present study demonstrated that SNHG16 is highly expressed in both the tissues of patients with OS, as well as OS cell lines, and its expression level was positively correlated with clinical stage and poor overall survival. Functional assays revealed that the depletion of SNHG16 inhibits OS growth, OS cell progression and promotes apoptosis both in vivo and in vitro. In addition, the present study revealed that microRNA-1285-3p expression levels can be decreased by SNHG16 acting as a ‘sponge’, and that this pathway takes part in OS tumor growth in vivo, and OS cell proliferation, invasion, migration and apoptosis in vitro. Conclusions The results from the present study demonstrate the role of lncRNA SNHG16 in OS progression, which is SNHG16 might exert oncogenic role in osteosarcoma (OS) by acting as a ceRNA of miR-1285-3p, and it may become a novel target in OS therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

LncRNA SNHG16 contributes to osteosarcoma progression by acting as a ceRNA of miR-1285-3p

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Zhang et al reported that LEF1-AS1 knockdown significantly inhibits cell survival, proliferation and migration while enhancing cell apoptosis and inducing G0/G1 cell cycle arrest in oral squamous cell carcinoma, indicating a carcinogenic role of LEF1-AS1 in tumour progression [ 25 ]. Furthermore, LEF1-AS1 also has been proven to be positively correlated with lymph node metastasis and advanced stage during ovarian cancer progression, and enhanced LEF1-AS1 expression may predict a poor prognosis [ 26 ]. Nevertheless, the role of LEF1-AS1 and the underlying mechanism by which it functions in AIPC progression as remained unclear.…”

Section: Discussionmentioning

confidence: 99%

LncRNA LEF1-AS1 promotes metastasis of prostatic carcinoma via the Wnt/β-catenin pathway

Yang

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background Long noncoding RNAs (lncRNAs) are important functional regulators of many biological processes of cancers. However, the mechanisms by which lncRNAs modulate androgen-independent prostate cancer (AIPC) development remain largely unknown. Methods Next-generation sequencing technology and RT-qPCR were used to assess LEF1-AS1 expression level in AIPC tissues and adjacent normal tissues. Functional in vitro experiments, including colony formation, EDU and transwell assays were performed to assess the role of LEF1-AS1 in AIPC. Xenograft assays were conducted to assess the effect of LEF1-AS1 on cell proliferation in vivo. Chromatin immunoprecipitation (ChIP) and RNA binding protein immunoprecipitation (RIP) assays were performed to elucidate the regulatory network of LEF1-AS1. Results The next-generation sequencing results showed that LEF1-AS1 is significantly overexpressed in AIPC. Furthermore, our RT-qPCR assay data showed that LEF1-AS1 is overexpressed in AIPC tissues. Functional experiments showed that LEF1-AS1 promotes the proliferation, migration, invasion and angiogenic ability of AIPC cells in vitro and tumour growth in vivo by recruiting the transcription factor C-myb to the promoter of FZD2, inducing its transcription. Furthermore, LEF1-AS1 was shown to function as a competing endogenous RNA (ceRNA) that sponges miR-328 to activate CD44. Conclusion In summary, the results of our present study revealed that LEF1-AS1 acts as a tumour promoter in the progression of AIPC. Furthermore, the results revealed that LEF1-AS1 functions as a ceRNA and regulates Wnt/β-catenin pathway activity via FZD2 and CD44. Our results provide new insights into the mechanism that links the function of LEF1-AS1 with AIPC and suggests that LEF1-AS1 may serve as a novel potential target for the improvement of AIPC therapy.

show abstract

“…Zhang et al reported that LEF1-AS1 knockdown inhibited cell survival, proliferation and migration, whereas enhanced cell apoptosis and induced G0/G1 cell cycle arrest in oral squamous cell carcinoma, hinting a cancerigenic role of LEF1-AS1 in tumour progression [25]. Furthermore, LEF1-AS1 also has been proven to be positively correlated with lymph node metastasis and advanced stage in ovarian cancer and Enhanced expression of LEF1-AS1 may predict a poor prognosis [26]. Nevertheless, the role of LEF1-AS1 and the underlying mechanism in AIPC progression remain unclear.…”

Section: Discussionmentioning

confidence: 99%

LncRNA LEF1-AS1 promotes metastasis of prostatic carcinoma via the Wnt/β-catenin pathway

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Long noncoding RNAs (lncRNAs), which are important functional regulators in cancer, have emerged as critical molecular regulators in various biological processes. However, the mechanisms by which LEF1-AS1 modulates Androgen-Independent Prostate Cancer (AIPC) development remain largely unknown.Methods: The LEF1-AS1 expression level was detected in tumour tissues and adjacent normal tissues of AIPC patients by using next-generation sequencing technology and qRT-PCR. Cell proliferation, migration and invasion were assessed by colony formation, EDU assays and transwell assays, respectively. Xenograft assay was conducted to determine the effect of LEF1-AS1 on cell proliferation in vivo.Results: LEF1-AS1 promoted the proliferation, migration, invasion and angiogenic ability of AIPC cells in vitro and in vivo. In this mechanism, LEF1-AS1 recruited the transcription factor C-myb to the promoter region of FZD2, which activated FZD2 transcription. Moreover, LEF1-AS1 functioned as a competing endogenous RNA (ceRNA) acting as a sponge for miR-328, which activated CD44.Conclusion: Collectively, these data indicate that LEF1-AS1 is a tumour promoter in the development of AIPC and that it may contribute to the improvement of AIPC diagnosis and therapy.

show abstract

<p>LncRNA LEF1-AS1 Promotes Ovarian Cancer Development Through Interacting with miR-1285-3p</p>

Cited by 20 publications

References 35 publications

LncRNA SNHG16 contributes to osteosarcoma progression by acting as a ceRNA of miR-1285-3p

LncRNA SNHG16 contributes to osteosarcoma progression by acting as a ceRNA of miR-1285-3p

LncRNA LEF1-AS1 promotes metastasis of prostatic carcinoma via the Wnt/β-catenin pathway

LncRNA LEF1-AS1 promotes metastasis of prostatic carcinoma via the Wnt/β-catenin pathway

Contact Info

Product

Resources

About